Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06.
Morinaga S, Takita M, Yoshizawa A, Kamei K, Nakamori S, Ishihara S, Kuramochi H, Yokoyama Y, Uchiyama T, Murohisa G, Ishigaki M, Todaka A, Fukutomi A. Morinaga S, et al. Among authors: kuramochi h. Pancreas. 2020 Nov/Dec;49(10):1372-1377. doi: 10.1097/MPA.0000000000001692. Pancreas. 2020. PMID: 33122527
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, Baba E, Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K. Sakai D, et al. Among authors: kuramochi h. Eur J Cancer. 2020 Aug;135:11-21. doi: 10.1016/j.ejca.2020.04.014. Epub 2020 Jun 8. Eur J Cancer. 2020. PMID: 32526634 Clinical Trial.
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H, Ishida H, Yamaguchi S, Kuramochi H, Fukazawa A, Sonoda H, Yoshimatsu K, Matsuda A, Hasegawa S, Sakamoto K, Otsuka T, Koda K; TAS CC3 Study Group.. Yoshida Y, et al. Among authors: kuramochi h. Int J Clin Oncol. 2021 Jan;26(1):111-117. doi: 10.1007/s10147-020-01794-8. Epub 2020 Oct 21. Int J Clin Oncol. 2021. PMID: 33083913 Clinical Trial.
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Tanioka H, Nagasaka T, Uno F, Inoue M, Okita H, Katata Y, Kanzaki H, Kuramochi H, Satake H, Shindo Y, Doi A, Nasu J, Yamashita H, Yamaguchi Y. Tanioka H, et al. Among authors: kuramochi h. BMC Cancer. 2019 Oct 11;19(1):941. doi: 10.1186/s12885-019-6163-6. BMC Cancer. 2019. PMID: 31604467 Free PMC article.
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Kuramochi H, Ando M, Itabashi M, Nakajima G, Kawakami K, Hamano M, Hirai E, Yokomizo H, Okuyama R, Araida T, Yoshimatsu K, Kameoka S, Hayashi K. Kuramochi H, et al. Cancer Chemother Pharmacol. 2017 Mar;79(3):579-585. doi: 10.1007/s00280-017-3255-3. Epub 2017 Feb 17. Cancer Chemother Pharmacol. 2017. PMID: 28213683 Clinical Trial.
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Moriwaki T, Nishina T, Sakai Y, Yamamoto Y, Shimada M, Ishida H, Amagai K, Sato M, Endo S, Negoro Y, Kuramochi H, Denda T, Hatachi Y, Ikezawa K, Nakajima G, Bando Y, Tsuji A, Yamamoto Y, Morimoto M, Kobayashi K, Hyodo I. Moriwaki T, et al. Among authors: kuramochi h. Jpn J Clin Oncol. 2022 Jul 8;52(7):725-734. doi: 10.1093/jjco/hyac073. Jpn J Clin Oncol. 2022. PMID: 35470391 Clinical Trial.
215 results